EGFR and non-small cell lung carcinoma: Similarly, the EGFR pathway is frequently dysregulated in cancers like non-small cell lung cancer (NSCLC) and colorectal cancer.248 EGFR mutations or overexpression lead to uncontrolled cell proliferation, and EGFR-targeted therapies have shown significant clinical benefits in specific patient subsets.